viewSilence Therapeutics PLC

Silence Therapeutics agrees second licensing deal potentially worth in excess of US$1.4bn

"Over the last year we have made great progress in our collaboration with Mallinckrodt and we are very pleased that they have exercised their option over two further complement targets," said chairman Iain Ross

Silence Therapeutics PLC -

Silence Therapeutics PLC (LON:SLN) has built on its deal with the US drug developer Mallinckrodt, which is licensing two additional assets from the UK firm in a deal that could ultimately be worth in excess of US$1.4bn.

Initially, however, the figures involved are more modest. The gene silencing specialist will fund all pre-clinical activity after which it will receive a US$2mln milestone payment.

It is then eligible to receive up to US$10mln in research ‘milestones’ per complement-targeted RNAi asset, and up to US$703mln per asset in clinical, regulatory and commercial milestones.

Silence will also receive tiered, low double-digit to high-teen royalties on net sales of any finished drug.

“Alongside our other recent deals with large pharma companies, this is further validation of our science; a testament to the quality of our data and our dedication to treat serious diseases with high unmet need," Silence chairman Iain Ross said in a statement.

Silence inked its initial two-asset tie-up with Mallinckrodt almost a year ago and the American group became an investor in the business.

The UK drug research group, which plans to list on the Nasdaq growth market, also has tie-ups with AstraZeneca and Takeda.

Quick facts: Silence Therapeutics PLC

Price: 456 GBX

Market: AIM
Market Cap: £377.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...



Market Report: FTSE 100 retreats as UK employment tumbles

Headlines from the Proactive UK newsroom. The FTSE100 was on the back foot as the new job numbers highlighted how business is suffering due to the pandemic. The blue chip-index shed 60 to 6,232. People on UK payrolls fell by 649,000 between March and June, according to the government....

4 weeks, 1 day ago

2 min read